Kacey B Wodowski Audiologist Medicare: Not Enrolled in Medicare Practice Location: 8 Lloyd Dr, Lower Apt., Cheektowaga, NY 14225 Phone: 716-548-0109 |
News Archive
While seemingly invincible teenage athletes at the height of good health and fitness aren't likely candidates for doctor's visits, even the fit need to visit a physician before practice. Sports physicals, often called pre-participation sports examinations, are key to making sure athletes are healthy enough to play and avoiding tragic occurrences, like sudden cardiac death, says a Saint Louis University sports medicine expert.
OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva's® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a "Notice of Allowance" accepting the Company's application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.
Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.
Terminally-ill homeless adults and their care providers must surmount many obstacles in the receipt and provision of palliative care, according to a University of Toronto scoping review of the available grey and peer-reviewed literature on this topic, published online this week in OMEGA - Journal of Death and Dying.
Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.
› Verified 2 days ago